Statistical methods applied to omics data: Predicting response to neoadjuvant therapy in breast cancer

Current Opinion in Oncology

Volumn 26, Issue 6, 2014, Pages 576-583

  Ternès, Nils ^a,b   Arnedos, Monica ^a   Koscielny, Serge ^a   Michiels, Stefan ^a,b   Lanoy, Emilie ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Breast cancer; Clinical trial; Gene expression; Neoadjuvant

Indexed keywords

LETROZOLE;

ADJUVANT THERAPY; BREAST CANCER; CAUSAL ATTRIBUTION; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; GENOMICS; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS; TREATMENT RESPONSE; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; PROCEDURES;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOADJUVANT THERAPY;

EID: 84927604770     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000134     Document Type: Review

References (50)

1. Hoerl AE, Kennard RW. Ridge regression: biased estimation for nonorthogonal problems. Technometrics 1970; 42:80-86.
2. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Ser B 1996; 58:267-288.
3. Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Ser B 2005; 67:301-320.
4. Bøvelstad HM, Nygård S, Størvold HL, et al. Predicting survival from microarray data: a comparative study. Bioinformatics 2007; 23:2080-2087.
5. Maathuis MH, Kalisch M, Bühlmann P. Estimating high-dimensional intervention effects from observational data. Ann Stat 2009; 37:3133-3164.
6. Stekhoven DJ, Moraes I, Sveinbjörnsson G, et al. Causal stability ranking. Bioinformatics 2012; 28:2819-2823.
7. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360:790-800.
8. Ignatiadis M, Singhal SK, Desmedt C, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012; 30:1996-2004.
9. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011; 29:1578-1586.
10. Gao Q, Patani N, Dunbier AK, et al. Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response. Clin Cancer Res 2014; 20:2485-2494.
11. Horak CE, Pusztai L, Xing G, et al. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage breast cancer. Clin Cancer Res 2013; 19:1587-1595.
12. Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007; 8:1071-1078.
13. Bonnefoi H, Piccart M, Bogaerts J, et al. TP53 status for prediction of sensitivity to taxane versus nontaxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011; 12:527-539.
14. Baselga J, Zambetti M, Llombart-Cussac A, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009; 27:526-534.
15. Iwamoto T, Bianchini G, Booser D, et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 2011; 103:264-272.
16. Korde LA, Lusa L, McShane L, et al. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat 2010; 119:685-699.
17. Tabchy A, Valero V, Vidaurre T, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010; 16:5351-5361.
18. Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011; 305:1873-1881.
19. Chen YZ, Xue JY, Chen CM, et al. PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy. Cancer Chemother Pharmacol 2012; 70:637-644.
20. Gonzalez-Angulo AM, Iwamoto T, Liu S, et al. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 2012; 18:1109-1119.
21. Shen K, Qi Y, Song N, et al. Cell line derived multigene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial. BMC Med Genomics 2012; 5:51.
22. Dunbier AK, Ghazoui Z, Anderson H, et al. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Res 2013; 19:2775-2786.
23. Mulligan JM, Hill LA, Deharo S, et al. Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. J Natl Cancer Inst 2014; 106:djt335.
24. Singer CF, Klinglmüller F, Stratmann R, et al. Response prediction to neoadjuvant chemotherapy: comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay. PLoS One 2013; 8:e66573.
25. Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 2014; 15:R47.
26. Knudsen S, Jensen T, Hansen A, et al. Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients. PLoS One 2014; 9:e87415.
27. El-Dereny M, Rashwan N. Solving multicollinearity problem using ridge regression models. Int J Contemp Math Sci 2011; 6:585-600.
28. Goeman J. Package "penalized". 2012. Available from: www.cran.r-project.org/web/packages/penalized/penalized.pdf.
29. Zou H, Hastie T. Elastic-Net for Sparse Estimation and Sparse PCA. 2012. Available from: www.cran.r-project.org/web/packages/elasticnet/elasticnet.pdf.
30. Pearl J. Causality: models, reasoning and inference. New York, United States: Cambridge University Press; 2000.
31. Spirtes P, Glymour C, Scheines R. Causation, prediction, and search. 2nd ed London, United Kingdom: The MIT Press; 2000.
32. Kalisch M, Bühlmann P. Estimating high-dimensional directed acyclic graphs with the PC-algorithm. J Mach Learn Res 2007; 8:613-636.
33. Kalisch M, Mächler M, Colombo D, et al. Causal inference using graphical models with the R package pcalg. J Stat Softw 2012; 47:1-26.
34. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365:488-492.
35. Miller WR, Larionov A, Renshaw L, et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 2009; 27:1382-1387.
36. Miller WR, Larionov A, Anderson TJ, et al. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J 2012; 12:10-21.
37. Taminau J, Steenhoff D, Coletta A, et al. inSilicoDb: an R/Bioconductor package for accessing human Affymetrix expert-curated datasets from GEO. Bioinformatics 2011; 27:3204-3205.
38. McCall MN, Bolstad BM, Irizarry RA. Frozen robust multiarray analysis (fRMA). Biostatistics 2010; 11:242-253.
39. Li Q, Birkbak NJ, Gyorffy B, et al. Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics 2011; 12:474.
40. Wilson CL, Miller CJ. Simpleaffy: a BioConductor package for Affymetrix quality control and data analysis. Bioinformatics 2005; 21:3683-3685.
41. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14:5158-5165.
42. Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer: a study from the IMPACT trialists. J Clin Oncol 2005; 23:2477-2492.
43. Mackay A, Urruticoechea A, Dixon JM, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007; 9:R37.
44. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003; 63:6523-6531.
45. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 2007; 105 (Suppl 1):33-43.
46. Haibe-Kains B, Desmedt C, Loi S, et al. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 2012; 104:311-325.
47. Miller WR, Larionov AA, Renshaw L, et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 2007; 17:813-826.
48. Bedard PL, Singhal SK, Ignatiadis M, et al. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. Endocr Relat Cancer 2011; 18:721-730.
49. Mello-Grand M, Singh V, Ghimenti C, et al. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Res Treat 2010; 121:399-411.
50. Rebhan M, Chalifaćcaspi V, Prilusky J, Lancet D. GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics 1998; 14:656-664.